Neuphoria Therapeutics Inc (Nasdaq:NEUP), a late-stage biotechnology developing treatments for neuropsychiatric disorders, said on Wednesday that it will receive a USD15m milestone payment from US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, following the initiation of a Phase 2 clinical trial for MK-1167 in Alzheimer's disease.
The trial, evaluating the safety and efficacy of MK-1167 as an α7 nicotinic acetylcholine receptor positive allosteric modulator, is the second milestone achieved in the partnership.
Neuphoria's collaboration with Merck focuses on developing treatments for neuropsychiatric disorders, with the company eligible for up to USD450m in additional milestone payments. The agreement also includes royalties on net sales of any licensed products.
This payment reflects the progress of MK-1167 in advancing towards potential therapeutic use in Alzheimer's disease dementia.
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
The Los Angeles Trust for Children's Health Appoints Dr Sarah Rodman as New Executive Director
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
ACG to invest USD200m in US hard-shell capsule manufacturing
Charles River and X-Chem form strategic collaboration to accelerate hit identification
Merck reports long-term survival benefits of Keytruda in non-small cell lung cancer
Avacta reports promising Phase 1a data for faridoxorubicin at ESMO 2025